K4bwxkhdtysvva678xvr activ

ActivX Biosciences, Inc

5 Orders Completed
La Jolla, California, US

About ActivX Biosciences, Inc

Founded: 2000

ActivX is an emerging biopharmaceutical company that discovers and develops highly selective, best in class, small molecule drugs for major unmet medical needs. ActivX uses its unique technology to identify target and off-target activities of drug candidates in the protein kinase and protease families with an initial focus on the areas of hematology, oncology, metabolic and inflammatory diseases. Our core technology allows identification and development of highly selective drugs, lowering development risk.

The KiNativ™ platform provides an unrivaled ability to quantitatively profile kinase inhibitors against native kinases in virtually any cell or tissue lysate, including those derived from in vivo animal studies. This chemoproteomics technology assays kinase inhibition directly in biological samples where protein-protein interactions, differential phosphorylation, and other naturally occurring modifications are preserved. The ActivX universal kinase probes allow for a cross-species platform that supports kinase inhibitor characterization throughout the drug discovery process. Specific applications include the evaluation of inhibitor potency and specificity, target identification, hit validation, and hit-to-lead optimization. Moreover, the unique ability to directly assess target engagement in pre-clinical and clinical samples affords unparalleled potential to expedite drug development.

Recent Publications

  • KV Christensen, GP Smith, DS Williamson. Chapter Two-Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease. Progress in Medicinal Chemistry 56, 37-80
  • KL Lee, CM Ambler, DR Anderson, BP Boscoe, AG Bree, JI Brodfuehrer et al. Discovery of clinical candidate 1-{[(2S, 3S, 4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl] methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a potent, selective inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4), by fragment-based drug design. Journal of Medicinal Chemistry 2017
  • ML Cann, IM McDonald, MP East, GL Johnson, LM Graves. Measuring Kinase Activity—A Global Challenge. Journal of Cellular Biochemistry 2017
  • H Liu, X Feng, KN Ennis, CA Behrmann, P Sarma, TT Jiang, S Kofuji et al. Pharmacologic targeting of S6K1 in PTEN-deficient neoplasia. Cell reports 18 (9), 2088-2095
  • L Tan, D Gurbani, EL Weisberg, DS Jones, S Rao, WD Singer et al. Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorganic & medicinal chemistry 25 (4), 1320-1328
  • E Vakana, S Pratt, W Blosser, M Dowless, N Simpson, XJ Yuan, S Jaken et al. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Oncotarget 8 (6), 9251
  • Y Sun, JA Alberta, C Pilarz, D Calligaris, EJ Chadwick, SH Ramkissoon et al. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro-oncology 19 (6), 774-785
  • P Jones, RI Storer, YA Sabnis, FM Wakenhut, GA Whitlock, KS England et al. Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. Journal of medicinal chemistry 60 (2), 767-786

Our Services (10)


ic

Kinase Identification

Price on request
Request a quote for more information about this service.

ic

Hit to Lead and Lead Optimization

Price on request
Request a quote for more information about this service.

ic

Kinase Assays

Price on request
Request a quote for more information about this service.

ic

Drug Discovery & Development

Price on request
Request a quote for more information about this service.

ic

Biochemistry & Molecular Biology

Price on request
Request a quote for more information about this service.

ic

Biochemical Assays

Price on request
Request a quote for more information about this service.

ic

Drug Discovery

Price on request
Request a quote for more information about this service.

ic

Lead Identification and Validation

Price on request
Request a quote for more information about this service.

ic

Enzyme Assays

Price on request
Request a quote for more information about this service.

ic

Biology

Price on request
Request a quote for more information about this service.

Not finding what you're looking for?

Get info on this provider's capabilities without requesting a quote.
LD

Lorrie Daggett

VP Corporate Planning and Operations
  • Positive review for Drug Discovery & Development:

    September 2018

    "Data delivery timeline was met on time and ordering process was smooth. However, at times Tyzoon Nomanbhoy's responses to questions/comments can be very abrupt and damaging to the company-customer relationship."

ActivX Biosciences, Inc has not received any endorsements.